Delcath Systems (DCTH) 2.84 $DCTH
Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 11:10AM CDT
Sirona Dental Systems, Inc. (SIRO) anticipates adjusted earnings in the range of $3.60 to $3.70 per share for fiscal 2014, implying a growth of 6-9%.
Technical Coverage on Health Care Stocks -- Research on Delcath Systems, Zimmer Holdings, St. Jude Medical, and ZELTIQ Aesthetics
PR Newswire - Fri May 09, 12:00PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Delcath Systems Inc. (NASDAQ: DCTH), Zimmer Holdings Inc. (NYSE: ZMH), St. Jude Medical Inc. (NYSE: STJ) and ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ). Free technical research on DCTH, ZMH, STJ and ZLTQ can be downloaded upon signing up at:
ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
ArthroCare Corp.'s (ARTC) total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
Falling Earnings Estimates Signal Weakness Ahead for ABIOMED (ABMD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:52AM CDT
ABIOMED has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Delcath Reports 2014 First Quarter Results
PR Newswire - Wed May 07, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and corporate developments for the fiscal first quarter ended March 31, 2014. Highlights for the quarter and recent weeks subsequent to quarter end are as follows:
Mindray Medical Misses on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:54PM CDT
Mindray Medical International Limited (MR) continues to expect 2014 net revenues to grow at least 15% over 2013.
Mindray Medical International Limited (MR) Crumbles: Stock Falls by 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
Mindray has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:10AM CDT
Following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.
DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:32AM CDT
DexCom's (DXCM) total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million.
Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:22AM CDT
For 2014, Masimo Corporation (MASI) expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million.
Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:20AM CDT
Accuray Incorporated (ARAY) raised its total revenue guidance for fiscal 2014 to a range of $355 to $365 million from the previous range of $340 to $350 million.
Weakness Seen in The Spectranetics Corporation (SPNC) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
The Spectranetics Corporation has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
DELCATH TO REPORT FIRST QUARTER 2014 RESULTS ON MAY 7, 2014
Thomson Reuters ONE - Wed Apr 30, 3:02PM CDT
NEW YORK, NY - April 30, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, May 7, 2014 at 4:30 p.m. ET to discuss its financial results for the first quarter of 2014 ended March 31, 2014, and provide an update on recent corporate progress.
Teleflex 1Q Earnings Rise, Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 2:03PM CDT
For 2014, Teleflex continues to expect revenue growth between 6.0 and 8.0% versus 2013.
Global Ocular Melanoma Clinical Trials Review 2014
M2 - Wed Apr 30, 10:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7szcv/ocular_melanoma) has announced the addition of the "Ocular Melanoma Global Clinical Trials Review, H1, 2014" report to their offering. Ocular Melanoma Global Clinical Trials Review, H1, 2014" provides data on the Ocular Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ocular Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ocular Melanoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Delcath Systems, Inc. - National Cancer Institute - Case Comprehensive Cancer Center - USC Norris Comprehensive Cancer Center - University of California, Los Angeles - Memorial Sloan Kettering Cancer Center - Institut Curie - European Organization for Research and Treatment of Cancer - University of Southern California - Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/h7...r_melanoma
Luminex 1Q Earnings Rise 50%, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:13PM CDT
For 2014, Luminex reiterated its revenue guidance in the range of $225 to $240 million, reflecting an increase of 5 to 12% over 2013.
What Makes Intuitive Surgical (ISRG) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:59AM CDT
Intuitive Surgical (ISRG) has witnessed a significant price decline in the past four weeks and it has seen negative earnings estimate revisions for the current quarter and the current year. It could be time to get rid of the security before more losses hit your portfolio.
Bear of the Day: Intuitive Surgical (ISRG) - Bear of the Day
Eric Dutram - Zacks Investment Research - Mon Apr 28, 3:18AM CDT
Bear of the Day: Intuitive Surgical (ISRG) - Bear of the Day
Varian Medical Systems Beats, Earnings Flat Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:12PM CDT
Varian Medical Systems (VAR) retained its earnings per share guidance between $4.22 and $4.34 for the year, including a 16-cent charge for a patent litigation settlement.
Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 11:10AM CDT
Sirona Dental Systems, Inc. (SIRO) anticipates adjusted earnings in the range of $3.60 to $3.70 per share for fiscal 2014, implying a growth of 6-9%.
Technical Coverage on Health Care Stocks -- Research on Delcath Systems, Zimmer Holdings, St. Jude Medical, and ZELTIQ Aesthetics
PR Newswire - Fri May 09, 12:00PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Delcath Systems Inc. (NASDAQ: DCTH), Zimmer Holdings Inc. (NYSE: ZMH), St. Jude Medical Inc. (NYSE: STJ) and ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ). Free technical research on DCTH, ZMH, STJ and ZLTQ can be downloaded upon signing up at:
ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
ArthroCare Corp.'s (ARTC) total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
Falling Earnings Estimates Signal Weakness Ahead for ABIOMED (ABMD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:52AM CDT
ABIOMED has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Delcath Reports 2014 First Quarter Results
PR Newswire - Wed May 07, 3:01PM CDT
Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and corporate developments for the fiscal first quarter ended March 31, 2014. Highlights for the quarter and recent weeks subsequent to quarter end are as follows:
Mindray Medical Misses on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:54PM CDT
Mindray Medical International Limited (MR) continues to expect 2014 net revenues to grow at least 15% over 2013.
Mindray Medical International Limited (MR) Crumbles: Stock Falls by 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:50AM CDT
Mindray has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:10AM CDT
Following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.
DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:32AM CDT
DexCom's (DXCM) total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million.
Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:22AM CDT
For 2014, Masimo Corporation (MASI) expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million.
Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:20AM CDT
Accuray Incorporated (ARAY) raised its total revenue guidance for fiscal 2014 to a range of $355 to $365 million from the previous range of $340 to $350 million.
Weakness Seen in The Spectranetics Corporation (SPNC) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
The Spectranetics Corporation has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
DELCATH TO REPORT FIRST QUARTER 2014 RESULTS ON MAY 7, 2014
Thomson Reuters ONE - Wed Apr 30, 3:02PM CDT
NEW YORK, NY - April 30, 2014 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, May 7, 2014 at 4:30 p.m. ET to discuss its financial results for the first quarter of 2014 ended March 31, 2014, and provide an update on recent corporate progress.
Teleflex 1Q Earnings Rise, Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 2:03PM CDT
For 2014, Teleflex continues to expect revenue growth between 6.0 and 8.0% versus 2013.
Global Ocular Melanoma Clinical Trials Review 2014
M2 - Wed Apr 30, 10:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7szcv/ocular_melanoma) has announced the addition of the "Ocular Melanoma Global Clinical Trials Review, H1, 2014" report to their offering. Ocular Melanoma Global Clinical Trials Review, H1, 2014" provides data on the Ocular Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ocular Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ocular Melanoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Delcath Systems, Inc. - National Cancer Institute - Case Comprehensive Cancer Center - USC Norris Comprehensive Cancer Center - University of California, Los Angeles - Memorial Sloan Kettering Cancer Center - Institut Curie - European Organization for Research and Treatment of Cancer - University of Southern California - Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/h7...r_melanoma
Luminex 1Q Earnings Rise 50%, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:13PM CDT
For 2014, Luminex reiterated its revenue guidance in the range of $225 to $240 million, reflecting an increase of 5 to 12% over 2013.
What Makes Intuitive Surgical (ISRG) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:59AM CDT
Intuitive Surgical (ISRG) has witnessed a significant price decline in the past four weeks and it has seen negative earnings estimate revisions for the current quarter and the current year. It could be time to get rid of the security before more losses hit your portfolio.
Bear of the Day: Intuitive Surgical (ISRG) - Bear of the Day
Eric Dutram - Zacks Investment Research - Mon Apr 28, 3:18AM CDT
Bear of the Day: Intuitive Surgical (ISRG) - Bear of the Day
Varian Medical Systems Beats, Earnings Flat Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:12PM CDT
Varian Medical Systems (VAR) retained its earnings per share guidance between $4.22 and $4.34 for the year, including a 16-cent charge for a patent litigation settlement.
